Cancer News: Head and neck
Nivolumab prolongs overall survival and reduces side effects in patients with relapsed metastatic head and neck cancer.
Stereotactic radiation therapy used in patients with recurrent head and neck cancer can cause fewer side effects than traditional treatments.
Oropharyngeal cancer patients may avoid significant pain and disfigurement if treated with incisionless robotic surgery, a new study shows.
US regulators approved pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Treatment’s impact on quality of life should be considered when choosing treatment for head and neck squamous cell carcinoma, an analysis shows.
Vemurafenib, a drug targeting BRAF mutation, induced positive results in treating metastatic thyroid cancer patients harboring the mutation.
The use of cetuximab and radiation therapy compared with radiotherapy resulted in higher rate of laryngeal preservation in laryngeal cancer patients.
The immunotherapy nivolumab increased progression free survival with less adverse events in head and neck cancer patients.
Head and neck cancer patients treated with immunotherapy drug, Opdivo, increased their median overall survival, a new study reports.
Patients with head and neck cancer who underwent PET/CT-guided surveillance or planned neck dissection had similar survival rates.
Breast or thyroid cancer survivors are more likely to develop the other type later in life compared to women with no breast or thyroid cancer history.
A new study reveals that interrupting radiation therapy during cancer treatment may lead to cancer recurrence, especially for head and neck cancers.
Patients with difficult-to-treat and advanced head and neck cancer have more treatment options with immunotherapy and targeted therapy.
In a recent study assessing the physical, psychological, social and spiritual wellbeing of thyroid cancer survivors, a “poor” quality of life was reported.
A new study reveals that depression has a profound impact on five-year survival and recurrence in head and neck cancer patients.
Lenvatinib (Lenvima) benefited metastatic differentiated thyroid cancer patients across all common sites of metastasis, scientists reported.
Data from a phase 3 trial and various sub-analyses show that lenvatinib improved progression-free survival in patients with differentiated thyroid cancer.
Advance practice nurses can offer high-quality, cost-effective care in high-risk patients who receive chemo-radiation therapy for head and neck cancer, a new research shows.
Pembrolizumab (Keytruda) found to be beneficial for advanced head and neck cancer patients as it achieved to reduce tumors in size with mild side effects.
Patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy should avoid current smoking and heavy alcohol consumption, according to a new report.
Patients with advanced thyroid cancer benefited from a targeted therapy with sunitinib, a drug approved for treatment of several other cancers.
Breast cancer survivors found to be prone to thyroid cancer, especially within five years of their breast cancer diagnosis according to a new comparative analysis.
The FDA approved lenvatinib for the treatment of thyroid cancer, two months ahead of its initial approval date in April.
Lenvatinib improved progression-free survival in thyroid cancer patients but median overall survival was not reached and serious adverse events were recorded.
Head and neck cancers in young adults are more likely to be as a result of inherited factors, rather than lifestyle factors such as smoking or drinking alcohol.
Preliminary results from a phase 2 trial for a medication to help prevent oral mucositis have been positive for patients with head and neck cancer.
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck had improved outcomes from afatinib, compared to methotrexate, in a trial.
Patients with advanced laryngeal cancer appear to have better survival if treated with surgery, compared to non-surgical chemotherapy and radiation therapy.
The precise targeting and limited dosing of radiation via proton therapy is proving to be an advantage in ongoing efforts to reduce treatment side effects among head and neck cancer patients, according to a new study of pediatric patients from researchers at the Perelman School of Medicine at the University of Pennsylvania. The results were presented Monday at the 55th annual meeting of the American Society for Radiation Oncology (ASTRO) conference.
The use of an intensified form of radiotherapy in patients with locally advanced head and neck cancers can improve overall survival rates compared with standard radiation therapy, according to results from a large study to be presented at the 2013 European Cancer Congress (ECC2013).